(2020) Schizophrenia and macroprolactinoma: Is there a deep link? Advanced Biomedical Research. ISSN 2277-9175
|
Text
12289.pdf Download (424kB) | Preview |
Abstract
Prolactinomas are the most common type of functional pituitary tumors. Dopamine agonists is the most important drugs used in prolactinoma,have antagonistic effect with antipsychotic drugs used in schizophrenia. Conversely, dopamine antagonist drugs increase prolactin in patients with simultaneous schizophrenia. In the present case, we report a 29-year-old single male with schizophrenia who treated for 8 years with risperidone and presented with macroprolactinoma. Iatrogenic hyperprolactinemia is a well-known side effect of dopamine antagonist drugs for treatment in a patient with schizophrenia. On the other hand, it appears these drugs have the other side effects, such as drug- induced prolactinoma or boost growth.
| Item Type: | Article |
|---|---|
| Keywords: | Antipsychotic agents case reports dopamine antagonists prolactinoma schizophrenia HYPERPROLACTINEMIA DIAGNOSIS DOPAMINE |
| Subjects: | WD Disorders of Systemic, Metabolic or Environmental Origin, etc. > WD 200-226 Metabolic Diseases |
| Divisions: | Health Information Technology Research Center Isfahan Endocrine and Metabolism Research Center |
| Journal or Publication Title: | Advanced Biomedical Research |
| Journal Index: | ISI |
| Volume: | 9 |
| Number: | 1 |
| Identification Number: | https://doi.org/10.4103/abr.abr₉₆₂₀ |
| ISSN: | 2277-9175 |
| Depositing User: | Zahra Otroj |
| URI: | http://eprints.mui.ac.ir/id/eprint/12289 |
Actions (login required)
 |
View Item |